Recombinant Anti-WT1 Immunotherapeutic GSK2302024A

**Semantic type:** Pharmacologic Substance

**Definition:** An immunotherapeutic composed of the Wilms tumor 1 (WT1) and an as of yet undisclosed adjuvant, with potential antineoplastic activity. Upon administration, the immune system may be stimulated to exert a cytotoxic T-lymphocyte (CTL) response against WT1-expressing tumor cells. The adjuvant stimulates the immune system's response to WT1. WT1, a tumor-associated antigen (TAA) and transcription factor, is overexpressed in a variety of tumor cell types.

**Synonyms:** - ASCI GSK2302024A - GSK2302024A